Facts And Misconceptions About ePRO Cost-Effectiveness

By Nicole Latimer, CEO of Medrio

In mid-2020, as decentralized trial (DCT) formats were being readily adopted, there was a sense that technologies developed more than a decade earlier were finally being used; their promises of cost-effectiveness and enhanced data quality were in sight. Many of us in the industry vowed that there was #nogoingback [1] .

Two years later, whether the progress made in clinical research will be preserved is harder to predict. While some surveys [2] suggest decentralized trial technologies will increasingly be used in hybrid trials, other surveys, like the recent Tufts Center for the Study of Drug Development study [3], report that “a surprisingly small number of respondents indicated that they planned to use [DCT] technologies in the future.”

Multiple factors are driving the difference of opinion on DCT technologies and the lack of greater adoption. Including misperceptions about patients’ technological skills and confusion about country-specific regulations. This eBook will focus on the misconceptions around the cost-effectiveness of electronic patient-reported outcomes (ePRO) and also share key points to consider when evaluating various ePRO solutions.